EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables)

12 Months Ended

Dec. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Unrealized Gain (Loss) on Investments

Equity securities at fair value for the periods presented were comprised of the following:

Security Type	Cost		Gross Unrealized Gain		Gross Unrealized Loss		Fair Value
	(In thousands)
December 31, 2021:
Equity securities - Life Sciences Portfolio (Note 4)	$	56,037	$	262,811	$	(1,488)	$	317,360
Equity securities	43,822		2,068		(1,472)		44,418
Total	$	99,859	$	264,879	$	(2,960)	$	361,778
December 31, 2020:
Equity securities - Life Sciences Portfolio (Note 4)	$	32,765	$	72,689	$	(583)	$	104,871
Equity securities	4,086		1,410		(1,264)		4,232
Total	$	36,851	$	74,099	$	(1,847)	$	109,103

The consolidated statements of operations reflected the following net realized and unrealized gains from our Life Sciences Portfolio:

	Years Ended December 31,
	2021		2020
	(In thousands)
Change in fair value of equity securities of public companies	$	188,875	$	72,104
Change in fair value of equity securities without readily determinable fair value	—		103,751
Conversion of equity securities without readily determinable fair value    to equity securities of public companies	(102,067)		—
Gain (loss) on sale of equity securities of public companies	115,172		(3,930)
Gain on sale of prepaid investment and derivative	—		2,845
Net realized and unrealized gain	$	201,980	$	174,770